In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).
Watch the video and download the accompanying slides to learn about:
- The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
- Applying recent data to treatment sequencing in bone-dominant mCRPC
- Educating and supporting patients during treatment so they know what to expect
Clinical Takeaways
-
Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL
-
They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue
-
Real-world data support using 177Lu-PSMA in patients who previously received Ra-223
-
Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients